IN THIS ISSUE
Legislation & Regulation
Richard Mark Kirkner
Nonquantitative treatment limitations may be why care for mental health and substance abuse disorders isn’t keeping up with coverage gains.
Medication Management
Thomas Reinke
Some say gene editing platforms like CRISPR are a truer version of gene therapy because they are designed to home in on a particular genomic location.
Viewpoint
Nicolle Rychlick
Because physicians and health plan members both value choice, the current weak market for Inflectra and Renflexis could be a passing phase.
Book Review
Peter Boland
Tomorrow’s Medicine
Thomas Morrow, MD
Ingrezza and Austedo were approved last year. ICER calculations raise questions about their price.
News & Commentary